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A Simple Method for Noninvasive
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OBJECTIVES We sought to test whether the ratio of peak tricuspid regurgitant velocity (TRV, ms) to the
right ventricular outflow tract time-velocity integral (TVIRVOT, cm) obtained by Doppler
echocardiography (TRV/TVIRVOT) provides a clinically reliable method to determine
pulmonary vascular resistance (PVR).
BACKGROUND Pulmonary vascular resistance is an important hemodynamic variable used in the management
of patients with cardiovascular and pulmonary disease. Right-heart catheterization, with its
associated disadvantages, is required to determine PVR. However, a reliable noninvasive
method is unavailable.
METHODS Simultaneous Doppler echocardiographic examination and right-heart catheterization were
performed in 44 patients. The ratio of TRV/TVIRVOT was then correlated with invasive PVR
measurements using regression analysis. An equation was modeled to calculate PVR in Wood
units (WU) using echocardiography, and the results were compared with invasive PVR
measurements using the Bland-Altman analysis. Using receiver-operating characteristics
curve analysis, a cutoff value for the Doppler equation was generated to determine PVR
2WU.
RESULTS As calculated by Doppler echocardiography, TRV/TVIRVOT correlated well (r  0.929, 95%
confidence interval 0.87 to 0.96) with invasive PVR measurements. The Bland-Altman
analysis between PVR obtained invasively and that by echocardiography, using the equation:
PVR  TRV/TVIRVOT  10  0.16, showed satisfactory limits of agreement (mean 0 
0.41). A TRV/TVIRVOT cutoff value of 0.175 had a sensitivity of 77% and a specificity of
81% to determine PVR 2WU.
CONCLUSIONS Doppler echocardiography may provide a reliable, noninvasive method to determine
PVR. (J Am Coll Cardiol 2003;41:1021–7) © 2003 by the American College of Cardiology
Foundation
Pulmonary vascular resistance (PVR) is a hemodynamic
variable that contributes to the management of patients with
advanced cardiovascular and pulmonary conditions. It is
used to evaluate the response to pharmacologic therapy in
patients with congestive heart failure (1). Also, PVR is an
essential component of heart- and liver- transplant candi-
date evaluation (2) and in predicting both early and late
clinical outcomes (3,4). Moreover, PVR is an important
variable in deciding the surgical outcome of patients with
congenital heart disease (5). Pulmonary vascular resistance is
calculated invasively by the ratio of transpulmonary pressure
gradient (p) to transpulmonary flow (Qp) (6).
Doppler echocardiography has significantly impacted
clinical medicine by its ability to determine intracardiac
hemodynamics noninvasively. Since flow and pressure vari-
ables can be measured, we hypothesized that a measure of
PVR might be accurately obtained by Doppler-derived
variables.
METHODS
This study was approved by the Institutional Review Board.
A sample of 44 patients who had a pulmonary artery
catheter in place was evaluated. Each subject provided
written, informed consent. The patients’ demographic and
clinical characteristics are shown in Table 1. Doppler and
invasive measurements were obtained within 45 min of each
other. Tricuspid regurgitation grade2, as determined by
Doppler echocardiography, was exclusionary.
Invasive measurements. A Swan-Ganz catheter was used
for hemodynamic measurements. Pulmonary capillary
wedge pressure (PCWP), pulmonary artery systolic pressure
(PASP), pulmonary artery diastolic pressure, and mean
pulmonary artery pressure (MPAP) were measured.
Cardiac output was calculated by thermodilution as a
mean of three consecutive measurements not varying by
more than 10%.
The PVR in Wood units (WU) was calculated using the
equation:
PVR  MPAP  PCWP/cardiac output
Doppler measurements. Doppler echocardiography was
performed using the GE Vivid FiVe (GEMS, Milwaukee,
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Wisconsin) or Acuson Sequoia (Acuson, Mountain View,
California) ultrasound systems.
The right ventricular outflow tract time-velocity integral
(TVIRVOT) (cm) was obtained by placing a 1- to 2-mm
pulsed wave Doppler sample volume in the proximal right
ventricular outflow tract just within the pulmonary valve
when imaged from the parasternal short-axis view. The
sample volume was placed so that the closing but not
opening click of the pulmonary valve was visualized. Pulsed
wave Doppler was used rather than continuous wave Dopp-
ler to eliminate cases with increased pulmonary velocities
secondary to either pulmonary valve or peripheral pulmo-
nary artery stenosis.
Continuous wave Doppler was used to determine the
peak tricuspid regurgitant velocity (TRV) (m/s). The high-
est velocity obtained from multiple views was used. Agitated
saline was used to enhance suboptimal Doppler signals (7).
In patients with atrial fibrillation (n 3), the average of five
measurements were used. The TRV/TVIRVOT ratio was
then calculated (Figs. 1A, 1B, 2A, and 2B).
Individuals in whom both invasive measurements and
Doppler variables were obtained were blinded to each
other’s calculations.
Statistical analysis. SAS version 8.0 software was used for
statistical computations (SAS Institute Inc., Cary, North
Carolina). Linear regression analysis was generated between
invasive PVR (WU) (PVRCATH) and TRV/TVIRVOT, and
Pearson’s correlation coefficient was obtained. A regression
equation was derived in which a value for PVR (WU) was
modeled based on TRV/TVIRVOT (PVRECHO). Further-
more, a plot of PVRECHO compared with PVRCATH was
generated using the Bland-Altman analysis.
Using receiver-operating characteristics curves, a dichot-
omized PVR was analyzed based on TRV/TVIRVOT. A
logistic model was generated, and a cutoff value for TRV/
TVIRVOT with balanced sensitivity and specificity values
was obtained to predict elevated PVR values (PVR 2
WU). Confidence intervals were calculated for the sensitiv-
ity and specificity values by using the exact binomial
method. Another cutoff value was then generated to deter-
mine a higher specificity of predicting PVR 2 WU.
Twenty percent of the Doppler images were re-evaluated
to quantify the intra- and interobserver reliability by calcu-
lating the intraclass correlation coefficient (ICC 2patients/
[2patients 
2
error]). Confidence intervals for the ICC were
calculated using the method of Shrout and Fleiss (8).
RESULTS
Thirteen of our patients had increased right atrial pressure
(RAP) (8 mm Hg), whereas 20 had elevated mean left
atrial pressure (PCWP 12 mm Hg).
The linear regression analysis between PVRCATH and
TRV/TVIRVOT revealed a good correlation (r  0.93, 95%
confidence interval [CI] 0.87 to 0.96) for all patients (Fig.
3). The equation derived from the linear regression was:
PVRECHO  0.1618  10.006  TRV/TVIRVOT  error
Patients with elevated PCWP and RAP were evenly
distributed among the patient population (Fig. 4).
Using the Bland-Altman analysis, PVRECHO measure-
ments derived from this equation showed satisfactory limits
of agreement with PVRCATH (Fig. 5), with a mean value of
0.0  0.41 (SD). The PVRECHO and PVRCATH values
were well within one standard deviation (Figs. 1 and 2).
The area under the receiver-operating characteristics
curve was calculated at 0.916 (Fig. 6). A TRV/TVIRVOT
cutoff value of 0.175 provided the best-balanced sensitivity
(77%; 95% CI 46% to 96%) and specificity (81%; 95% CI
63% to 93%) to determine PVR 2 WU.
A TRV/TVIRVOT cutoff value of 0.2 provided a speci-
Abbreviations and Acronyms
CI  confidence interval
ICC  intraclass correlation coefficient
MPAP  mean pulmonary artery pressure
PASP  pulmonary artery systolic pressure
PCWP  pulmonary capillary wedge pressure
PVR  pulmonary vascular resistance
PVRCATH  invasive pulmonary vascular resistance
PVRECHO  pulmonary vascular resistance calculated by
echocardiography
Qp  transpulmonary flow
p  transpulmonary pressure gradient
RAP  right atrial pressure
TRV  peak tricuspid regurgitant velocity
TVIRVOT  right ventricular outflow tract time-velocity
integral
WU  Wood units
Table 1. Clinical and Demographic Characteristics of the
Patients
Characteristics Findings
Gender (M/F) 32/12
Mean age (range) in yrs 67 (47–90)
Mean ejection fraction (range) (%) 54 (20–75)
Mean of the mean pulmonary artery pressure (range)
(mm Hg)
25 (10–57)
Pulmonary capillary wedge pressure
Mean (range) (mm Hg) 14 (3–38)
12 mm Hg (n) 24
13–19 mm Hg (n) 8
20 mm Hg (n) 12
Right atrial pressure
8 mm Hg (n) 31
8 mm Hg (n) 13
Mean PVRCATH (range) (WU) 2 (0.7–6)
Referral diagnosis
Valvular heart disease (n  12)
Chest pain and exertional dyspnea (n  9)
CAD and exertional dyspnea (n  8)
Renal and liver transplant (n  6)
Acute respiratory failure (n  4)
Postoperative (n  3)
Cardiomyopathy (n  2)
CAD coronary artery disease; PVRCATH invasive pulmonary vascular resistance;
WU  Woods unit.
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Figure 1. Images showing peak tricuspid regurgitant velocity (TRV) and right ventricular outflow time-velocity integral (TVIRVOT) in a patient with normal
pulmonary vascular resistance (PVR). (A) TRV is 2.86 m/s. (B) TVIRVOT is 20.8 cm. The ratio of TRV/TVIRVOT  2.86/20.8  0.1375. PVRECHO 
0.1375 10 0.16 1.53 Woods units (WU) . This patient’s invasive PVR measurement was within 0.4 WU of the echocardiographic value (PVRCATH
 1.3 WU). PVRECHO  PVR in WU calculated based on the linear regression equation in which a value for PVR in WU was modeled based on
TRV/TVIRVOT. PVRCATH  invasive PVR.
Figure 2. Images showing TRV and TVIRVOT in a patient with elevated PVR. (A) TRV is 3.64 m/s. (B) TVIRVOT shows a clear deceleration of pulmonary
flow before the pulmonic valve closure click and is calculated at 6.5 cm. The ratio of TRV/TVIRVOT  3.64/6.5  0.56. PVRECHO  0.56  10  0.16
 5.76 WU . This patient’s invasive PVR measurement is also within 0.4 WU of the echocardiographic value (PVRCATH  6.0 WU). Abbreviations as
in Figure 1.
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Figure 3. Linear regression analysis between PVRCATH and TRV/TVIRVOT. The circle highlights the PVR cutoff value of 2 WU (r  0.929, 95%
confidence interval 0.87 to 0.96). Abbreviations as in Figure 1.
Figure 4. Linear regression analysis between PVRCATH and TRV/TVIRVOT. The correlation remained robust among all groups of patients. Patients with
normal left atrial pressure (LAP) and right atrial pressure (RAP) (open squares), elevated LAP and RAP (solid squares), elevated LAP and normal RAP
(solid triangles), and elevated RAP and normal LAP (open triangles) were evenly distributed among the study population. Abbreviations as in Figure 1.
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Figure 5. Bland-Altman analysis showing the limits of agreement between PVRECHO and PVRCATH. Abbreviations as in Figure 1.
Figure 6. Receiver-operating characteristics curve. A TRV/TVIRVOT cutoff value of 0.175 provided the best-balanced sensitivity (77%) and specificity
(81%) to determine patients with a PVR value 2 WU. (Area under the curve  0.916.) Abbreviations as in Figure 1.
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ficity of 94% and a sensitivity of 70% to determine PVR 2
WU. Thus, by using a TRV/TVIRVOT cutoff value of 0.2,
the PVR could have been determined noninvasively to be
2 WU in 94% of patients.
The ICC and CI for inter- and intraobserver reliabilities
were 0.99 (95% CI 0.95 to 1.0) and 0.99 (95% CI 0.98 to
1.0), respectively.
DISCUSSION
Pulmonary vascular resistance is directly related to p and
inversely related to Qp (6). Thus, TRV and TVIRVOT can
be used as correlates of p and Qp, respectively (9,10). As
PVR increases, changes in TVIRVOT and TRV occur in
opposite directions (9,11). In accordance with the Bernoulli
equation, TRV will increase as the PASP increases
(9,12,13). However, both hyperdynamic flow states and true
pulmonary vascular disease can elevate PASP; therefore, a
measure of Qp is crucial. As PVR increases, there is earlier
and enhanced reflection of the pressure wave propagated
from the RVOT into the pulmonary trunk. This is reflected
by a conformational change in TVIRVOT, where mid-
systolic notching and premature deceleration of pulmonary
flow occur, leading to a decreased right ventricular ejection
time (11,14–17). The Doppler-derived ratio of TRV/
TVIRVOT was hence hypothesized as a good correlate of
PVR.
Previous investigators have described the use of various
Doppler parameters to evaluate PVR (11,15–23). These
efforts have focused primarily on the timing of events such
as right ventricular pre-ejection and ejection times, acceler-
ation time of the RVOT velocity, and flow propagation
velocities. These studies support the notion that a confor-
mational change in TVIRVOT occurs with increasing PVR.
However, these methods require obtaining additional infor-
mation than routinely acquired with less robust test char-
acteristics.
Based on our results, we propose a simplified equation for
noninvasive calculation of PVR:
PVR(WU)  10  TRV/TVIRVOT
We also propose that in patients with increased PASP on
Doppler echocardiography and TRV/TVIRVOT 0.2, an
elevated PVR is suggested, and these patients may require
further invasive workup. However, in patients with TRV/
TVIRVOT0.2, PVR values are likely to be normal, even in
the presence of Doppler evidence of increased PASP.
Study limitations. Proper alignment of the ultrasound
beam is a crucial factor to ensure adequate determination of
TRV and TVIRVOT.
Detection of TRV is crucial. The TRV signal could not
be obtained in only one patient and was excluded. Agitated
saline and ultrasound contrast agents can also enhance the
Doppler signal when needed (7).
A correction for heart rate in TVIRVOT was not made, as
all patients had a heart rate between 60 and 100 beats/min.
Heart rate correction may be required for extreme varia-
tions.
Possible confounding hemodynamic variables that were
not included in our Doppler equation include correlates of
RAP and PCWP. Patients in whom the results of this study
may be beneficial will likely have elevated RAP and PCWP.
However, despite the presence of these patients in our
study, the correlation remained robust (Fig. 4).
Thermodilution was used to calculate cardiac output,
which may be inaccurate in the presence of moderate or
severe tricuspid regurgitation; thus, those patients were
excluded. Further studies will be needed to determine the
applicability of this formula to those groups of patients in
whom the Fick method was used for calculation of cardiac
output.
Anatomic variations of the right-heart structures may
interfere with Doppler variables. Further studies will be
needed to determine the applicability of this formula to
patients with congenital heart disease, shunts, or pulmonary
artery dilation who were not included in our study.
Conclusions. Noninvasive determination of PVR is possi-
ble using variables that are routinely obtained by Doppler
echocardiography. Increased PASP may be secondary to
increased transpulmonary flow or abnormal PVR. Patients
with TRV/TVIRVOT 0.2 are likely to have low PVR
values (2 WU), and pulmonary vascular disease may be
excluded despite increased PASP by Doppler.
We propose that the term “increased pulmonary pres-
sures” may be preferred to describe all patients with in-
creased PASP. However, the term “pulmonary hyperten-
sion” may be more appropriately used in patients who also
have increased PVR.
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